Optimized microfluidic formulation and organic excipients for improved lipid nanoparticle mediated genome editing-Reference-Cited by-同舟云学术

Optimized microfluidic formulation and organic excipients for improved lipid nanoparticle mediated genome editing

Published:2024 Issue:16 Volume:24 Page:3790-3801
ISSN:1473-0197
Container-title:Lab on a Chip
language:en
Short-container-title:Lab Chip

Author:

Palanki Rohan¹²^ORCID,Han Emily L.¹,Murray Amanda M.¹,Maganti Rohin¹²,Tang Sophia¹,Swingle Kelsey L.¹^ORCID,Kim Dongyoon¹,Yamagata Hannah¹^ORCID,Safford Hannah C.¹^ORCID,Mrksich Kaitlin¹^ORCID,Peranteau William H.²,Mitchell Michael J.¹³⁴⁵⁶^ORCID

Affiliation:

1. Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, 19104, USA

2. Center for Fetal Research, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA

3. Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

4. Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

5. Penn Institute for RNA Innovation, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

6. Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

Abstract

Our work elucidates the importance of LNP formulation parameters, including microfluidic flow rate and organic excipient identity, for in vivo gene editing and presents an optimized delivery platform for the treatment of metabolic liver disease.

Funder

Division of Intramural Research

National Center for Advancing Translational Sciences

National Science Foundation Graduate Research Fellowship Program

Division of Diabetes, Endocrinology, and Metabolic Diseases

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/LC/D4LC00283K

Reference43 articles.

1. The promise and challenge of therapeutic genome editing

2. Therapeutic genome editing: prospects and challenges

3. Delivery technologies for in utero gene therapy

4. Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors

5. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis